Cryoport to Present at the J.P. Morgan 40th Annual Healthcare Conference

Download as PDF

NASHVILLE, Tenn., Jan. 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer and Robert Stefanovich, the Company's Chief Financial Officer will be presenting at the J.P. Morgan 40th Annual Healthcare conference taking place virtually from January 10 - 13, 2022.  Mr. Shelton will be presenting on Wednesday, January 12, 2022, at 9:00 a.m. ET. Additionally, Mr. Shelton, Mr. Stefanovich, and Thomas Heinzen, Vice President of Investor Relations and Corporate Development will be participating in 1x1 virtual meetings with attendees during the conference.

At the appointed time, interested parties may listen to Mr. Shelton's presentation by clicking here.  The webcast can also be accessed from the Company's website www.cryoport.com in the Investor Relations section under Events & Presentations. The webcast replay will be available for 30 days following the live event.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), headquartered in Nashville, TN, is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. With 33 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform provides mission-critical solutions, services, and products to Biopharma, Reproductive Medicine, and Animal Health customers worldwide. In addition to its standard setting supply chain solutions, Cryoport is the world's largest manufacturer of cryogenic systems and one of the largest life science focused specialty couriers. As of September 30, 2021, Cryoport supported eight commercial cell and gene therapies and 582 regenerative medicine clinical trials in over 150 countries with 70 of these trials in Phase 3.

For more information, visit www.cryoport.com or follow @cryoport on Twitter at www.twitter.com/cryoport for live updates.

Forward Looking Statements

Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, plans, strategy, acquisitions, including CRYOPDP and MVE Biological Solutions, financial results and financial condition. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors discussed in the Company's Securities and Exchange Commission ("SEC") reports including, but not limited to, the Company's Annual Report on Form 10-K for the three and twelve months ended December 31, 2020 and any subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-present-at-the-jp-morgan-40th-annual-healthcare-conference-301454328.html

SOURCE Cryoport, Inc.

Released January 5, 2022